GSK (GSK) announced that that China’s National Medical Products Administration, NMPA, has approved Exdensur as add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients aged 12 years and older. The approval of Exdensur in severe asthma is based on data from the SWIFT-1 and SWIFT-2 phase III trials. In these studies, depemokimab demonstrated sustained exacerbation reduction with two doses per year versus placebo, both plus standard of care.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s New Efimosfermin Alfa Trial Signals Renewed Push Into Fatty Liver Disease
- GSK announces EMA accepted for review the MAA for use of bepirovirsen
- M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
- GSK announces risvutatug rezetecan received ODD from Japan’s Ministry of Health
- GSK Advances New Phase 3 Trial in Hard-to-Treat Ovarian Cancer: What Investors Should Watch